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Abstract
Midkine (MDK) is a heparin-binding growth factor involved in growth, survival, migration, and differentiation of var-
ious target cells and dysregulation of MDK signaling is implicated in a variety of inflammatory diseases and can-
cers. Although MDK has been reported to act on endothelial cells and to have proangiogenic effects, the exact role
of MDK in angiogenesis is poorly defined. Here, we report that MDK is actually a modulator of angiogenesis and
that it can abrogate the vascular endothelial growth factor A (VEGF-A)–induced proliferation of human micro-
vascular endothelial cells in vitro through the downregulation of proangiogenic cytokines and through the upregu-
lation of the antiangiogenic factor, tissue inhibitor of metalloproteinase 2. Phosphorylation of vascular endothelial
growth factor receptor 2 (VEGFR-2) and of downstream signaling molecules, such as phosphatidylinositol-3-kinase
and mitogen-activated protein kinases, is also impaired. Moreover, MDK downregulates VEGF-A–induced neo-
vascularization and vascular permeability in vivo. We propose a model in which MDK is a new modulator of the
VEGF-A–VEGFR-2 axis.
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Introduction
Angiogenesis is the generation of new blood vessels from preexisting
microvasculature and is regulated by a number of growth factors,
among which the vascular endothelial growth factor (VEGF) family
of proteins is most prominent [1]. Because tumor growth and metas-
tasis depend on new blood vessel formation, angiogenesis has become
an attractive target for cancer therapy [2]. Vascular endothelial growth
factor family members exert their activities by binding to three struc-
turally related receptor tyrosine kinases, VEGF receptor (VEGFR)-1,
-2, and -3. The prominent VEGF-A isoform exerts most of its biologic
activities, such as endothelial cell (EC) proliferation, migration, survival,
and permeability, by activating VEGFR-2 [1,3,4]. Although EC prolif-
eration is an important component of angiogenesis, VEGF has rela-
tively weak mitogenic activity compared to other growth factors, such
as basic fibroblast growth factor (bFGF) [1,3]. It is thought that at least
part of the success of anti-VEGF strategies in the clinic can be attributed
to the potent activity of VEGF on vascular permeability [4,5].
The growth factor Midkine (MDK), also known as Neurite
growth–promoting factor 2, is a 13-kDa heparin-binding protein that
promotes the growth, survival, migration, and differentiation of vari-
ous cell types [6–8]. Midkine shares 50% identity in amino acid se-
quence with Pleiotrophin, and together, they represent the two members
of a distinct family of heparin-binding growth factors [7,8]. Several
reports suggest that MDK is a ligand for Syndecan-3, anaplastic
lymphoma kinase, low-density lipoprotein receptor–related protein,
α4β1- and α6β1-integrin, and the receptor-like protein-tyrosine
phosphatase-zeta [6,8]. Clinical reports indicate that MDK is over-
expressed in a variety of human carcinomas and that high levels of
MDK in patient serum correlate with poor clinical outcome [9–11].
Furthermore, high MDK expression levels in primary human tu-
mors were shown to correlate with increased tumor angiogenesis
[12]. It has also been reported that in xenografts from two cancer cell
lines of epithelial origin, overexpression of the MDK gene can cause
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increased angiogenicity, resulting in enhanced malignant proliferation
of cancer cells [13,14]. Taken together, an increasing number of
studies suggest that MDK is a candidate molecular target for the
therapy for carcinomas. However, unlike its close homolog Pleiotro-
phin, MDK’s biologic significance in angiogenesis in general and its
mechanism of action in ECs in particular still remains to be clarified.
Our study addresses the complex role of MDK in VEGF signaling,
using primary human microvascular ECs (HMVECs) as a model sys-
tem. In contrast to previously published results, which are primarily
based on overexpression experiments in epithelial cancer cell lines,
our data show that MDK can be a potent negative modulator of
VEGF-A–induced proangiogenic activities in vitro and in vivo and
shed new light on the role of MDK in angiogenesis.
Materials and Methods
Cell Lines and Reagents
Primary HMVECs were obtained from Lonza Inc. (Allendale, NJ)
and were cultured according to the suppliers’ protocol. The human an-
giogenesis antibody array (TranSignal Angiogenesis Antibody Array)
was purchased from Panomics Inc. (Fremont, CA). BrdU Incorpora-
tion and Cell Death Detection ELISAplus assay kits were purchased
from Roche Applied Science (Indianapolis, IN). Antibodies raised
against the following proteins were used: phosphotyrosine-specific
antibody [mouse monoclonal antibody (mAb): 4G10 (PY); UBI (now
Millipore), Temecula, CA], phospho–VEGFR-2 antibodies [rabbit
mAb (rmAb): Y1175 (19A10); Cell Signaling Technology Inc.,
Danvers, MA], VEGFR-2 antibody [rabbit polyclonal antibody
(pAb); Santa Cruz Biotechnology, Santa Cruz, CA], p85 antibody
(ascitic fluid; UBI), phospho-specific extracellular-regulated kinase
(ERK) 1/2 antibody (pAb; Cell Signaling), β-actin (ascitic fluid; Sigma,
St. Louis, MO). Horseradish peroxidase–coupled secondary antibodies
were purchased from Jackson Laboratories Inc. (West Grove, PA). Bo-
vine serum albumin (BSA) and Evans blue were from Sigma. Fertilized
special pathogen-free eggs were purchased from Charles River (St.
Louis, MO). Recombinant human VEGF-A, MDK, tissue inhibitor
of metalloproteinase 2 (TIMP-2), bFGF, and human transforming
growth factor alpha (TGF-α), tumor necrosis factor alpha (TNF-α),
and TIMP-2 ELISA kits (HS Quantikine) were purchased from
R&D Systems Inc. (Minneapolis, MN). We also expressed MDK in
Escherichia coli and Pichia pastoris following published protocols. The
MDK preparations were purified to homogeneity without detectable
contaminants using affinity chromatography, ion exchange, and gel fil-
tration chromatography. The biologic activity of MDK preparations
was confirmed in neurite outgrowth assays. All MDK preparations
demonstrated similar purities and activities, and we used the commer-
cially available MDK for all assays presented here. Collagen I–coated
culture dishes were from BD Biosciences (Bedford, MA).
Western Immunoblot Analysis and Cytokine Analysis
Western blot analysis was done as described previously [15]. Briefly,
HMVECs were plated onto collagen I–coated culture plates and
serum-starved (0.1% fetal bovine serum in endothelial cell basal
medium 2 for 24 hours containing 10 ng/ml heparin). Midkine,
VEGF-A, or both were added in the indicated time points and main-
tained at 37°C. After growth factor stimulation, cells were lysed;
lysates were cleared before protein concentrations were determined.
To analyze the cytokines secreted by HMVECs, cells were treated
as follows: 2 ml of conditioned medium were collected after 72 hours
and cytokines were detected either by probing the angiogenesis anti-
body array or by performing the corresponding ELISAs following the
respective supplier’s protocols.
Proliferation, Bromodeoxyuridine Incorporation,
and Apoptosis Assay
Human microvascular ECs were plated at a density of 8 × 104 /ml
onto collagen I–coated 96-well culture plates in complete media
(serum and growth factors: microvascular endothelial growth media 2),
incubated for 24 hours, and subsequently serum-starved for 24 hours in
endothelial cell basal medium 2 supplemented with 5% fetal bovine
serum. Human microvascular ECs were either left untreated or chal-
lenged with 25 ng/ml VEGF-A, 10 ng/ml MDK, or both growth fac-
tors as indicated. As a positive control, complete media was added. All
media contained 10 ng/ml heparin. Cells were incubated for 5 days, and
cell number was quantified using a reagent (Cell Titer Glo; Promega,
Madison, WI) according to the manufacturer’s protocol.
Bromodeoxyuridine (BrdU) Incorporation and apoptosis assays were
performed concurrently under similar conditions as previously men-
tioned, with the exception that cells were challenged with the indicated
proteins in the presence of BrdU for 48 hours. The extent of the in-
corporated BrdU and the increase of apoptotic events were quantified
according to the manufacturer’s protocols.
Chick Chorioallantoic Membrane Assay
The chick chorioallantoic membrane assay (CAM assay) was per-
formed as described elsewhere [16]. Briefly, fertilized eggs (n = 10 per
group) were incubated at 38°C in an egg incubator for 9 days. Eggs
were candled to verify the viability of each embryo and to localize
blood vessels. The growth factors were applied directly on the mem-
brane in a relatively avascular region. Phosphate-buffered saline
(PBS) and VEGF-A served as negative and positive controls. Midkine
was tested in the absence or presence of VEGF. Twenty nanograms of
each growth factor was used at a concentration of 2 μg/ml. After the
injection, eggs were placed in the incubator for 48 hours, and the
angiogenic response was visually scored using a dissecting micro-
scope. This study was performed double-blinded, and representative
micrographs are shown.
Miles Vascular Permeability Assay
The Miles vascular permeability assay (Miles assay) was performed
as described previously [17]. Briefly, the back skin of Balb/c mice was
depilated 24 hours before the experiment, and each treatment group
consisted of three mice. Evans blue dye (100 μl of a 1% solution in
0.9% NaCl) was injected intravenously into mice. After 10 minutes,
50 μl of human VEGF-A (1 ng/μl), MDK (1 ng/μl), VEGF-A and
MDK (2 ng/μl), or PBS were injected intradermally into the depilated
back skin. Animals were euthanized, and an area of skin that included
the entire injection site was removed. Extravasated Evans blue dye
bound to plasma proteins was extracted from the skin by incubation
in formamide for 24 hours at 60°C, and the fluorescence of the ex-
tracted dye was measured in a plate reader at 620 nm/590 nm.
Rat Corneal Angiogenesis Assay
All in vivo experiments were conducted in accordance with the
guidelines of the Amgen Animal Care and Use Committee. Corneal
angiogenesis was induced in female CD rats (Charles River Labora-
tories, Inc., Wilmington, MA) as described [18]. Briefly, 0.6-mm-
diameter circular discs of Nylaflo membrane (Pall Corp., Ann Arbor,
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MI) were incubated in PBS containing 0.1% BSA, 0.1% BSA with
10 μM VEGF (R&D Systems Inc.), or 0.1% BSA with 10, 30, or
100 μM MDK [Chemicon (now Millipore)] for 1 hour at 4°C. A
single disc was inserted into a pocket in the corneal stroma of anesthe-
tized rats. After 7 days, the corneas were photographed using an oph-
thalmic slit lamp (Nikon Instruments, Melville, NY), and numerical
data were generated from the digital images using an image analysis
software (MetaMorph v4.5; Universal Imaging, Downingtown, PA).
For each corneal image, the number of blood vessels intersecting the
midpoint between the disc and the limbus was counted. Values repre-
sent the group mean ± SEM (n = 8 per group). Statistical significance
was assessed by analysis of variance followed by Fisher’s post hoc test.
Results and Discussion
To elucidate the physiological effect of MDK in angiogenesis, we
used HMVECs as a model system. Because α4β1- and α6β1-integrins
Figure 1. Midkine-induced upregulation of TIMP-2 and downregulation of TGF-α and TNF-α inhibits VEGF-A–mediated proliferation and
BrdU incorporation of HMVECs. (A) Midkine suppresses the proliferation of ECs. Cell number was determined by the measurement of
intracellular ATP content (Cell Titer Glo) every 24 hours for 3 days in octuplicates. (B) Midkine elevates TIMP-2 secretion and down-
regulates expression of TGF-α and TGF-α in HMVECs. Conditioned medium of stimulated HMVECs was analyzed after 72 hours using
an antibody array (see Materials and Methods). (C) Midkine abrogates VEGF-A–induced BrdU incorporation in HMVECs. Bromodeoxy-
uridine incorporation assay with HMVECs was performed similarly in panel (A) for 48 hours in hexaduplicates. Midkine and TIMP-2 were
used in two different concentrations as indicated. Symbols indicate mean; bars, SD.
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were described as functional receptors for MDK and β1-integrins me-
diate adhesion of HMVEC to collagen I matrices [19], we initially
performed an in vitro proliferation assay on collagen I–coated plates
(Figure 1). Cells were serum-starved for 24 hours and either left un-
treated or challenged with VEGF-A, MDK, or both growth factors
together. As a positive control, cells were stimulated in the presence
of complete growth medium (CM group). We observed almost a
three- and six-fold growth induction of HMVECs in the presence
of VEGF-A and in the positive control CM group, respectively.
However, MDK alone suppressed proliferation and even abolished
VEGF-A–induced proliferation of HMVECs. We also performed pro-
liferation experiments with human umbilical vein ECs under identical
conditions and obtained similar results (data not shown). These results
are unexpected, because MDK has been reported to act as a mitogen
on other cell types, e.g. epithelial cells or fibroblasts (reviewed in the
study of Muramatsu [20]), and suggest a distinct role of MDK in ECs.
To elucidate the molecular basis of our findings, we investigated
whether MDK stimulation induces the secretion of antiangiogenic fac-
tors. We used an array with immobilized antibodies against 19 selected
soluble proteins related to angiogenesis and performed the same ex-
periment under identical conditions. After 72 hours, the conditioned
media of treated HMVECs were collected and analyzed for secreted
proteins (Figure 1B). After normalization, untreated and MDK-treated
HMVECs showed no difference in cytokine secretion (Figure 1B, left
and middle right panels), whereas VEGF-A treatment alone led to in-
creased secretion of the proangiogenic factors TGF-α and TNF-α [21]
and the antiangiogenic factor TIMP-2 [21] (Figure 1B, middle left
panel ). However, in the presence of MDK and VEGF-A, the secretion
of TGF-α and TNF-α was downregulated and the expression of
TIMP-2 was significantly increased (Figure 1B, right panel ). To further
substantiate our finding, we also quantified the amount of secreted
TGF-α, TNF-α, and TIMP-2 by performing ELISAs, where we
observed the same effect (Table 1). It has been shown that TIMP-2
abrogates VEGF-A–induced EC proliferation in vitro and angiogene-
sis in vivo through binding to α3β1-integrins, leading to enhanced
protein-tyrosine phosphatase activity and downregulation of tyrosyl-
phosphorylated VEGFR-2 [22].
Therefore, we speculated that MDK-induced upregulation of
TIMP-2 downregulates VEGF-A–mediated proliferation. To test
our hypothesis and confirm our previous result, we performed BrdU
incorporation assays under similar conditions for 48 hours. We in-
cluded MDK and TIMP-2 as VEGF-A antagonistic factors in two
different concentrations, respectively (Figure 1C ). Midkine abro-
gated VEGF-A–induced S-phase entry in a dose-dependent manner,
indicating that MDK antagonizes VEGF-A signaling. Exogenously
added TIMP-2 also diminished VEGF-A–mediated S-phase entry
similar to MDK, consistent with the postulated mechanism. DNA
fragmentation assays demonstrate that the observed growth-inhibitory
effects are a direct result of growth inhibition, as opposed to an in-
crease in apoptosis (see Figure W1).
To see if MDK treatment had an antagonistic effect on VEGFR-2
tyrosine phosphorylation, serum-starved HMVECs were either left un-
treated, challenged with MDK or VEGF-A, or pretreated with MDK or
TIMP-2 for 20 minutes before stimulation with VEGF-A (Figure 2A).
VEGFR-2 was immunoprecipitated, and its tyrosine phosphorylation
status was detected with the phosphotyrosine antibody 4G10 (PY).
We observed that VEGF-A stimulation increased tyrosine phosphoryla-
tion of VEGFR-2, whereas pretreatment with MDK inhibited the
VEGF-induced phosphorylation of VEGFR-2 (Figure 2A, lanes 2 and
4 ). Additionally, pretreatment with TIMP-2 abrogated VEGF-A–
induced phosphorylation of VEGFR-2 (Figure 2A, lane 6 ). We then
analyzed one of two major autophosphorylated tyrosines 1175 (Y1175)
of VEGFR-2 in the presence of MDK and TIMP-2 using a phospho-
specific antibody (Figure W1). We observed that MDK and
TIMP-2 similarly abrogated VEGF-A–induced phosphorylation of
VEGFR-2 at Y1175, which corroborates our previous observation. Be-
cause VEGF-A–induced survival and mitogenicity is thought to be
mainly regulated through recruitment of the signal-transducer phospha-
tidylinositol-3-OH-kinase (PI3K) to tyrosyl-phosphorylated VEGFR-2
[21], we also investigated the phosphorylation of the PI3K p85 subunit
under similar experimental conditions (Figure 2B). As expected, p85
phosphorylation was enhanced on VEGF-A stimulation. However, pre-
treatment with MDK before VEGF-A stimulation abolished p85 tyro-
sine phosphorylation to levels indistinguishable from untreated cells
(Figure 2B, left panel ). ErbB2 phosphorylation, which is not regulated
by VEGF or MDK, was used as a specificity control (Figure 2B, right
panel ). Taken together, these data show that MDK can modulate the
VEGF-A signal at the plasma membrane, altering the phosphorylation
status of the critical p85 binding sites, thereby impairing the activation of
PI3K by VEGFR-2. Consequently, signaling events downstream of
PI3K, such as mitogen-activated protein kinase and AKT activation,
should also be impaired after MDK pretreatment in HMVECs. To test
this hypothesis, we performed a time-course experiment (Figure 2C ).
Human microvascular ECs were plated onto collagen I–coated plates,
serum-starved, and either left untreated, challenged with VEGF-A and
MDK, or pretreated with MDK before VEGF-A stimulation for the in-
dicated periods of time. Subsequently, cells were lysed and ERK1/2 phos-
phorylation levels were analyzed using phospho-specific ERK1/2
antibodies (Figure 2B). Untreated or MDK-treated cells were indistin-
guishable and showed no elevated ERK1/2 phosphorylation. Consistent
with the literature, VEGF-A treatment led to increased ERK1/2 phos-
phorylation at all time points (10, 30, and 60 minutes). Pretreatment
with MDK decreased the VEGF-induced ERK1/2 phosphorylation at
all time points. We then tested if MDK influences VEGF-A–mediated
AKT phosphorylation (Figure 2D). AKT phosphorylation was strongly
downregulated in the presence of MDK. As a control, we also pretreated
the cells with TIMP-2 before VEGF-A stimulation and observed the
same effect. Basic fibroblast growth factor–induced AKT activation
was used as a specificity control and was not inhibited by MDK, indi-
cating that MDK specifically downregulates VEGF-A signaling. These
data support the notion that MDK negatively modulates VEGF-A–
induced signaling pathways.
To further substantiate our findings, we investigated the effects of
MDK on VEGF-induced angiogenesis in vivo. We first focused on
primary network formation in the CAM assay [16]. We used fertil-
ized special pathogen-free eggs and challenged them either with PBS,
MDK or VEGF-A alone or in combination. This experiment was
Table 1. Quantification of MDK-Induced Secretion of TGF-α, TNF-α, and TIMP-2 by ELISA.
TGF-α (pg/ml) TNF-α (pg/ml) TIMP-2 (pg/ml)
NS 1069 ± 227 1.019 ± 0.825 358.0 ± 223.0
VEGF 2234 ± 610 3.738 ± 0.703 4311 ± 1150
MDK 923.3 ± 36.0 0.673 ± 0.679 388.0 ± 140.0
VEGF + MDK 1222 ± 383 0.832 ± 0.428 6217 ± 637
Values represent the group mean ± SEM.
Quantification has been measured by ELISA using human-specific antibodies against indicated
antigens. Qualitative trends correspond to previously observed results in Figure 1B.
NS indicates not stimulated.
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performed double-blinded, and after 48 hours, the angiogenic re-
sponse was visually scored (Figure 3A).
Again, PBS- and MDK-treated eggs displayed no angiogenic re-
sponse (Figure 3A, top left and right panels). Consistent with published
data, VEGF-A promoted neovascularization, leading to the formation
of a primary network, whereas MDK- and VEGF-A-treated eggs failed
to form a capillary network (Figure 3A, lower left and right panels). This
result demonstrates for the first time an antiangiogenic effect of MDK
on VEGF-A–induced signaling events in an in vivo setting.
This observation directly contradicts an older report, which states that
MDK can induce angiogenesis in a rabbit cornea model [14]. To address
this issue, we also tested MDK in the rat cornea assay, but did not ob-
serve a statistically significant stimulation, confirming that MDK alone
does not act as a proangiogenic factor in this context (see Figure W1).
These differences might be explained by the reagents used in the studies.
Whereas we were able to use a highly purified recombinantMDK, earlier
studies were limited to at best partially purified conditioned media
from MDK-transfected mammalian cell lines, raising the possibility that
the observed effects were not directly mediated by MDK.
Because it is well known that VEGF-A induces strong vascular per-
meability, we then examined if MDK could also abrogate VEGF-A–
induced vascular permeability in vivo. To test MDK’s antiangiogenic
properties in combination with VEGF-A, we performed the Miles
assay [17] (Figure 3B). We injected either PBS, VEGF-A, and MDK
alone or a combination of VEGF-A and MDK. Compared to PBS,
MDK treatment alone led to a decrease in vascular permeability, where-
as VEGF-A alone induced permeability as expected (Figure 3B). Inject-
ing MDK and VEGF-A together failed to induce vascular leakage,
corroborating our previous observations that MDK acts as an antago-
nist in VEGF-A signaling in ECs.
Figure 2. MDK inhibits VEGF-A–mediated VEGFR-2, AKT, and mitogen-activated protein kinase phosphorylation in HMVECs. Serum-
starved HMVECs, plated on collagen I–coated plates, were either stimulated with VEGF-A (20 ng/ml) and MDK (10 μg/ml) or pretreated
with MDK and TIMP-2 (100 ng/ml) before VEGF-A stimulation for the indicated time points. Cell lysates were subjected to immuno-
precipitation using antibodies against VEGFR-2 (VEGFR-2; A), p85 (p85; B, left panel), or ErbB2 (ErbB2; B, right panel). Tyrosine phos-
phorylation was analyzed by Western blot analysis (WB) with monoclonal anti-phosphotyrosine antibody (α-PY); phosphorylation of
ERK1/2 and AKT 1 were analyzed by Western blot analysis (WB) of whole-cell lysates (WCL) with phospho-specific anti–ERK1/2 antibody
(PT/Y-ERK1/2; C, top panel), or anti–phospho-AKT antibody (S-473; D, top panel), respectively. Protein levels were checked by reblotting
with antibodies against VEGFR-2 (A, lower panel) or β-actin (C and D, lower panel). Arrows indicate the detected proteins. Note that
ErbB2 phosphorylation status serves as a specificity control for MDK and VEGF-A stimulation.
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Most previously published studies focused on the role of MDK on
the growth of epithelial cell lines in vitro and in vivo, and it has been
suggested, primarily based on circumstantial evidence, that MDK
might play a proangiogenic role [13]. To the best of our knowledge,
highly purified recombinant MDK has not been directly studied in
combination with VEGF-A in HMVEC or in any in vivo angiogenic
model systems. Our data clearly indicate that MDK can antagonize
VEGF-A–induced signaling events both in vitro and in vivo.
Some discrepancies between this study and previously published
observations linking MDK to angiogenesis can be explained by the
different cell types that were studied. It was previously concluded
that MDK is an attractive target for therapeutic intervention in vari-
ous cancers, and this conclusion was based primarily on its effect on
cancer cell lines of epithelial origin and its expression in human tu-
mors. Our findings demonstrate that the role of MDK in tumori-
genesis is more complex than previously appreciated. In light of the
seemingly dual role of this secreted factor, promoting growth and sur-
vival of epithelial cells on one hand and interfering with the function
of the proangiogenic factor VEGF-A on ECs on the other, a prediction
of the potential therapeutic benefit of an anti-MDK strategy is very
difficult and likely to be highly context-dependent.
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Figure W1. MDK has no influence on survival of HMVECs. (A) DNA fragmentation-assays with HMVECs was performed similarly in
Figure 1A for 48 hours in hexaduplicates. Midkine and TIMP-2 were used in two different concentrations as indicated. Please note that
the absorbance values above the individual bars in the apoptosis assay display no difference in apoptotic events in all treatment groups.
Symbols indicate mean; bars, SD. Midkine inhibits VEGF-A–mediated VEGFR-2 phosphorylation in HMVECs. (B) Cells were stimulated
and lysates prepared similarly in Figure 2A. Cell lysats were subjected to immunoprecipitation using antibodies against VEGFR-2
(VEGFR-2). Tyrosine phosphorylation was analyzed by Western blot analysis (WB) with phospho-specific anti–phopspho-VEGFR-2
(Y1175) antibody (B, top panel). Protein levels were checked by reblotting with antibodies against VEGFR-2 (B, lower panel). Midkine
does not promote significant angiogenesis in the rat cornea angiogenesis model. (C) Corneal angiogenesis was induced in female CD
rats (eight animals per group) with either 10 μM VEGF or the indicated amounts of MDK. After 7 days, the corneas were photographed,
and for each image, the number of blood vessels intersecting the midpoint between the disc and the limbus was measured. Values rep-
resent the group mean ± standard error of the mean. Statistical significance was assessed by analysis of variance followed by Fisher’s
post hoc test.
